Chinese biomedical company MingMed Biotechnology Co Ltd on Tuesday reported positive results from its Phase II clinical trial of QA102 in patients with intermediate dry age-related macular degeneration (AMD).

Study results were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting in Denver, Colorado.

Intermediate dry AMD is a chronic, progressive retinal disease marked by large drusen and pigmentary changes, representing a significant risk for conversion to advanced AMD.

Study QA102-CS201 is a phase 2, double-masked, randomised, placebo-controlled study, conducted in 150 subjects with intermediate atrophic AMD randomised 1:1:1 to oral QA102 200 or 400 mg, or placebo BID for up to 15 months.

Following 12 months of treatment, the mean change in drusen volume was reduced by 59.2% in QA102 400 mg group relative to the placebo group. Although the primary efficacy endpoint did not demonstrate a statistically significant difference between groups, the growth rate in drusen volume was reduced 118.2% (p=0.017) and the growth rate in square-root transformed GA area reduced by 42.7% in 400 mg group relative to placebo (p=0.026). MingMed Biotech said that in general, QA102 demonstrates the potential to slow down the progression of intermediate dry AMD with an acceptable safety profile.